The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...
Zacks.com on MSN5h
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...
Hosted on MSN6d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatmentRyoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...
17hon MSNOpinion
If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the ...
to approve Mesoblast Limited's allogenic, bone marrow-derived mesenchymal stromal cell (MSC) product, RYONCIL® (remestemcel-L) for pediatric, steroid-refractory, acute Graft-versus-Host-Disease ...
Half of these patients do not respond to first-line steroid treatment. RYONCIL® will now provide a clinically effective option to meet the significant mortality and life-changing impacts of ...
The approval marks the first stem cell therapy for the condition and will be marketed under the brand name Ryoncil. SR-aGVHD, a life-threatening condition, affects about 25% of the 1,500 children ...
The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback